Last reviewed 2026-04-22 · How we verify

GC3110B vaccine

Green Cross Corporation · Phase 3 active Biologic

GC3110B vaccine is a Therapeutic cancer vaccine Biologic drug developed by Green Cross Corporation. It is currently in Phase 3 development for Advanced or metastatic cancer (specific indication under investigation in phase 3). Also known as: GC3110B.

GC3110B is a therapeutic cancer vaccine designed to stimulate the immune system to recognize and attack cancer cells expressing specific tumor-associated antigens.

GC3110B is a therapeutic cancer vaccine designed to stimulate the immune system to recognize and attack cancer cells expressing specific tumor-associated antigens. Used for Advanced or metastatic cancer (specific indication under investigation in phase 3).

At a glance

Generic name	GC3110B vaccine
Also known as	GC3110B
Sponsor	Green Cross Corporation
Drug class	Therapeutic cancer vaccine
Modality	Biologic
Therapeutic area	Oncology
Phase	Phase 3

Mechanism of action

The vaccine works by activating dendritic cells and T-cell responses against tumor antigens, enabling the patient's immune system to target and eliminate cancer cells. This approach aims to provide durable anti-tumor immunity by training the body's own immune defenses to recognize and destroy malignant cells.

Approved indications

Advanced or metastatic cancer (specific indication under investigation in phase 3)

Common side effects

Injection site reactions
Fever
Fatigue
Myalgia

Key clinical trials

A Study to Evaluate Efficacy and Safety of GC3110B in Healthy Adults (PHASE3)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

GC3110B vaccine CI brief — competitive landscape report
GC3110B vaccine updates RSS · CI watch RSS
Green Cross Corporation portfolio CI

Frequently asked questions about GC3110B vaccine

What is GC3110B vaccine?

GC3110B vaccine is a Therapeutic cancer vaccine drug developed by Green Cross Corporation, indicated for Advanced or metastatic cancer (specific indication under investigation in phase 3).

How does GC3110B vaccine work?

GC3110B is a therapeutic cancer vaccine designed to stimulate the immune system to recognize and attack cancer cells expressing specific tumor-associated antigens.

What is GC3110B vaccine used for?

GC3110B vaccine is indicated for Advanced or metastatic cancer (specific indication under investigation in phase 3).

Who makes GC3110B vaccine?

GC3110B vaccine is developed by Green Cross Corporation (see full Green Cross Corporation pipeline at /company/green-cross-corporation).

Is GC3110B vaccine also known as anything else?

GC3110B vaccine is also known as GC3110B.

What drug class is GC3110B vaccine in?

GC3110B vaccine belongs to the Therapeutic cancer vaccine class. See all Therapeutic cancer vaccine drugs at /class/therapeutic-cancer-vaccine.

What development phase is GC3110B vaccine in?

GC3110B vaccine is in Phase 3.

What are the side effects of GC3110B vaccine?

Common side effects of GC3110B vaccine include Injection site reactions, Fever, Fatigue, Myalgia.

Drug class: All Therapeutic cancer vaccine drugs
Manufacturer: Green Cross Corporation — full pipeline
Therapeutic area: All drugs in Oncology
Indication: Drugs for Advanced or metastatic cancer (specific indication under investigation in phase 3)
Also known as: GC3110B
Compare: GC3110B vaccine vs similar drugs
Pricing: GC3110B vaccine cost, discount & access